Co-diagnostics, inc. jv cosara receives clearance from indian regulators for influenza multiplex pcr test

The clinical laboratory real-time pcr multiplex test was designed using co-dx co-primers™ and licensed by the cdsco for use in diagnostic procedures salt lake city , march 7, 2024 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx) (the "company" or "co-dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that cosara diagnostics pvt ltd ("cosara," or the "jv"), its joint venture for manufacturing and sales in india, has received clearance by the central drugs standard control organization ("cdsco") in india to manufacture and sell its saraplex™ influenza multiplex (ifm) test kit to clinical laboratories as an in vitro diagnostic ("ivd") for the detection and differentiation of influenza a and influenza b. cosara's new real-time multiplex pcr test is built on the company's patented co-primers™ technology and designed to simultaneously detect influenza a (h1n1, h3n2, h7n9, h1n2, h5n1, h2n2, h9n2, h10n8, h5n6, h7n7, h7n4, h7n2 and h2n1), influenza b (yamagata and victoria strains) and to differentiate between h1n1 and h3n2.
CODX Ratings Summary
CODX Quant Ranking